The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Bayer's Eylea wins approval in Europe to treat retinal vein occlusion.....           EMA accepts MAA for Amgen's myeloma drug Kyprolis.....           Portola's factor Xa inhibitor antidote andexanet alfa gets FDA orphan drug status.....           EMA grants orphan drug status for Tolero's leukemia drug alvocidib.....           ObsEva releases positive results from Phase I trial of OBE001 to treat preterm labour.....           Columbia to begin Phase II trial of lidocaine bioadhesive 10% gel.....           Triphase, Sunnybrook to advance development new bi-specific antibody for cancer patients.....           Sanofi's fight for Toujeo market share won't be easy, analysts say.....           SC's top court backs Risperdal verdict against J&J, but cuts penalty to $136M.....           Pharma wins another round in fight against dreaded drug reimportation.....           Valeant rolls out prelim data on its newly purchased cancer vaccine Provenge.....           GlaxoSmithKline's new chairman will climb aboard months earlier than expected.....           Bayer counts on consumer health, pharma growth to power 2015.....           GSK CEO Witty's pay whacked as U.K.'s largest drugmaker struggles to right itself.....           USPTO issues two patents covering Ocata?s immune-modulatory cell technology.....           Amgen reports positive results from Phase III study of AMG 416 with cinacalcet.....           Lupin enters into clinical research partnership with Acceliant.....           AstraZeneca, Orca to develop new drugs for autoimmune diseases.....           Sanofi's diabetes drug Toujeo gets FDA approval.....           FDA accepts for review Teva's NDA for pain management tablets.....           FDA approves Actavis' antibacterial drug Avycaz to treat cIAI and cUTI.....           Eisai's Phase III trial of sarcoma drug Halaven meets primary endpoint.....           USPTO issues two patents covering Ocata?s immune-modulatory cell technology.....           Amgen reports positive results from Phase III study of AMG 416 with cinacalcet.....           Lupin enters into clinical research partnership with Acceliant.....           Takeda will grow again in the coming year, COO Weber promises.....           California lawmaker calling for more pricing transparency for costly meds.....           J&J loses first court battle over Risperdal's breast-growth side effects.....           As Shire gears up to push Vyvanse for binge eating, critics worry about abuse.....           Sidelined after tampering incident, GSK's alli is back on sale.....           Dr. Reddy's drug prices in crosshairs of two states.....           Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg.....           Ireland's Shire buys Meritage Pharma for $70m.....           Merck, MPP to expand access to pediatric formulations of HIV drug raltegravir.....           Pfizer's Phase II trial of meningococcal group B vaccine meets co-primary immunogenicity objectives.....           Ipsen secures option to buy Canbex Therapeutics.....           Teva's Phase IIb chronic migraine trial of TEV-48125 meets primary and secondary endpoints.....           Actavis seeks FDA approval to market generic ulcerative colitis drug Uceris.....           FDA approves Novartis's multiple myeloma drug Farydak.....           Researchers review use of aspirin for cardiovascular disease prevention.....           India?s Elder Pharma expands its Solo range of OTC products.....           Takeda makes an M&A move in Turkey.....           Turning to Twitter, MD Anderson doc launches campaign against cancer drug prices.....           Baxter picks HQ for biopharma spinoff, and it's just up the road.....           Valeant's low Salix price may leave room for other bids.....           Actavis' buyout of Allergan could trigger $100M golden parachute for Pyott.....           Consumer group petitions FDA to pull generic antifungal med.....           Novartis agrees to FTC?s conditions to acquire GSK?s oncology drugs.....           Cyclenium and Fundación MEDINA partner to discover anti-infective drug candidates.....           Rigel, Bristol-Myers Squibb partner to develop cancer immunotherapies.....           NGM, Merck collaborate to develop biologic therapies for various diseases.....           Researchers complete Gardasil 9 HPV vaccine?s international phase 2/3 trial.....           New Sanofi chief's ?4M signing bonus 'incomprehensible' to French officials.....           Bayer reportedly close to diabetes device sale worth up to $2.3B.....           FDA hands Lupin plant 6 black marks, along with ANDA approval.....           With Salix buy, Valeant bets $10B on GI market growth.....           J&J awaits jury verdict over Risperdal patient's breast development.....           Canadian paper backpedals from Gardasil side effects story.....           Valeant to buy Salix Pharmaceuticals for $14.5bn.....           Researchers complete Gardasil 9 HPV vaccine?s international phase 2/3 trial.....           Actavis secures final US FDA approval for Buprenorphine sublingual tablets.....           Sosei acquires biotechnology company Heptares Therapeutics for $400m.....           US FDA accepts Pfizer's sNDA for priority review of Rapamune to treat LAM.....           MedImmune, NIST partner to advance drug discovery and manufacturing.....           New Sanofi chief's ?4 million signing bonus 'incomprehensible' to French officials.....           Targeted Medical enters into distribution agreement with J-Network in Japan.....           Sun billionaire Shanghvi becomes India's richest person.....           Bayer feels sting of mixed decision from NICE for Eylea's use in diabetics.....           Ariad activists strike up proxy fight to replace CEO Berger.....           Valeant closing in on $160-per-share Salix deal: Reuters.....           Ex-Merck analyst pleads guilty to insider trading.....           Brandicourt's departure piles on the exec shuffling at Bayer.....           Takeda, UK?s QMUL partner to develop new therapies for gastrointestinal diseases.....           Genmab, BioNovion to jointly develop immuno-oncology targets with DuoBody technology.....           Kite expands manufacturing capabilities for CAR and TCR cancer immunotherapy products.....           Valeo Pharma enters into distribution deal with Questcor for Synacthen Depot in Canada.....           CEL-SCI gets Malaysian approval to initiate Phase III trial of cancer drug Multikine.....           Genentech's melanoma drug combination gets FDA priority review.....           FDA approves Celgene's Revlimid in combination with dexamethasone to treat multiple myeloma.....           aTyr Pharma's Resolaris gets EMA orphan drug status for FSHD.....           Ferring buys two Phase III ready orthobiologic products from BioSET.....           Seattle submits supplemental BLA to FDA for Phase III Aethera trial of Adcetris in HL patients.....           Particle Sciences produces clinical supplies for Kinex's KX2-361 to treat glioblastoma.....           NICE, drugmakers reject analysis that price watchdog is too generous.....           Regeneron's Eylea beats Roche's Lucentis in new head-to-head study.....           FDA grants Celgene's Revlimid new use as it moves toward $10B in sales.....           Lilly extends study of highly anticipated cholesterol fighter.....           Want Actavis? Prepare to pay up, CEO says.....           Residents want to sue Roche before it gives up New Jersey campus.....           Sanofi makes it official--Brandicourt is its man.....           Sanofi, Lead Pharma to develop new autoimmune treatments.....           Teva to commercialize Eagle?s bendamustine rapid infusion product to treat CLL and NHL.....           Here's a switcheroo: HIV activists target Gilead for holding back on Truvada marketing.....           Why call us Allergan? Because brands are the name of Actavis' new game.....           Pharma's top 10 M&A deals of 2014.....           Remicade's U.S. patent rejection could open up early rivalry with Celltrion biosim.....           Amphastar pays some rebates after price of overdose drug doubles.....           Who's the new king of the drug launch hill? Hint: It's all in the Gilead family.....           Pharma wanted pricey orphan meds, and now it's got 'em in record numbers.....           Teva launches generic Lovenox and Zyvox in US.....           VistaGen, NIMH partner for Phase II trial of AV-101 to treat major depressive disorder.....           MediVector completes enrollment in two Phase III trials of favipiravir to treat influenza.....           Galderma makes Soolantra Cream, 1% available in US for rosacea patients.....           Adapt Pharma gets FDA fast track status for intranasal naloxone to treat opioid overdose.....           Agilvax, Humabs to develop targeted vaccines and immunotherapies.....           Lupin, Celon to jointly develop generic asthma drug.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Recent meetings

APS Freeze drying and alternative drying technologies for parenterals

28 January 2015 - Loughborough

Freeze drying - is there an alternative process technology to consider for your biopharmaceuticals?

A very successful one day meeting was held to look at the latest challenges and opportunities in the preservation of biopharmaceuticals. The meeting explored new developments in the established technology of freeze drying and discussed possible alternatives of spray drying, protein crystallisation and supercritical fluid drying of biopharmaceuticals.

Read more...

Latest News
DMU 3rd Quality by Design Symposium
MONDAY, 16 FEBRUARY 2015
24th & 25th March 2015 Leicester Tigers, Leicester After two successful symposia in 2013/2014 we are delighted to be hosting the Third Quality by Design Symposium on March 24-25th 2015. We planned this event to bring together academics, regulators and industrial experts to share academic research aligned to the QbD agenda as well as progress in ‘real life’ QbD implementation. The meeting will focus on Continuous Process and Biopharmaceuticals. Attendees’ remarks from the 2nd symposium in April 2014: •“I thoroughly enjoyed the day and I learnt a lot. I will be there for sure next year” •“It was perfectly organised and attracted a lot of interesting people” •“Engaging senior leaders from the big Pharma is really important. The Symposium was very enjoyable, great speakers and a great opportunity to catch up with people” Why Attend? •Last year 120 delegates attended the symposium (70% from industry) •Learn from senior leaders from industry about the latest development in Biopharmaceuticals and Continuous Manufacturing •Network, build relationships and collaborative opportunities Contacts Walkiria Schlindwein – Chair E: wss@dmu.ac.uk Jude Lewis – Administrator E: jlewis@dmu.ac.uk General Enquiries E: qbd@dmu.ac.uk http://www.qbd-dmu.co.uk/symposium-2015/enrol-now/.
APS Industrial Insights 2015
FRIDAY, 6 FEBRUARY 2015
16-17th April. PFIZER AT DISCOVERY PARK, SANDWICH. Two day event for undergraduate and postgraduate students exploring opportunities in the pharmaceutical industry. As a student attending you are able to get a first-hand insight into the Pharmaceutical Industry by a series of talks by key people within the Pharmaceutical Industry and a tour of the pharmaceutical research and manufacturing facilities at Discovery Park.. Choosing the right career path...A done deal or still deciding?. Industrial Insights 2015 offers opportunities to present a poster of your work, network with experienced pharmaceutical scientists including members of the NSFG committee, and have your CV reviewed by an industry professional.. Industrial Insights is organised by The Academy of Pharmaceutical Sciences New Scientist Focus Group (NSFG).. Feedback from Industrial Insights 2014 “A mind-blowing experience which gave me the unique opportunity to explore a wide range of career options available within the pharmaceutical industry and most importantly, network with pharmaceutical scientists from various fields.”. “A must go to event for those passionate about pursuing a career in the pharmaceutical industry: insightful, informative and enjoyable!”. For further information, to see the programme and to register, please visit us online here:. http://www.apsgb.co.uk/EVENTS/20150416/. .
APS Particle Engineering - Joint Meeting with SSPC
MONDAY, 2 FEBRUARY 2015
Venue: Trinity College, Dublin Monday 13th and Tuesday 14th April 2015. Particle engineering: the first stage for successful pharmaceutical formulation The delivery of a robust formulation process which successfully delivers the active ingredient reproducibly throughout the shelf life of a product is a challenge that formulation scientists face every day. Quite frequently variable input materials need to be “accommodated” by adjusting the formulation process or, even worse failure in performance testing can result in failed batches and potentially delays in supplying the market. By controlling, or even designing the input material a number of opportunities where simpler and cheaper formulations/processes, more rapid development and more robust processes can begin to emerge. Engineering of formulations that have reproducible or even predictable performance should start during the particle formation stage. Historically drug substance and drug product groups have worked very separately but more recently a firm collaboration can help identify the “right particles” and methods to produce them on scale. This symposium will provide world leading knowledge and case studies from both academia and industry in all the key aspects around particle engineering: Particle formation, isolation/drying, particle processing, particle assessment and particle performance. It is a must attend for both scientists and managers in pharmaceutical development and manufacture and will also appeal to scientific community in related industries such as food, FMCG and agrochemicals. This meeting is a partnership event bringing together the Materials Science Focus Group of the APS with the Solid State Pharmaceutical Cluster of Ireland. Opportunities will be available for displaying posters and also for exhibitors of scientific equipment/services. Please contact APS secretariat for more details. The event is to be held at Trinity College Dublin and as this is a partnership event demand is likely to be high for the limited places hence please be sure to reserve your place early to avoid disappointment.. For full details, please visit us on line here: http://www.apsgb.co.uk/EVENTS/20150413/Default.asp.
APS Bioequivalence of Orally Inhaled Drug Products: Establishing the Scientific Basis for Regulatory Acceptance of In Vitro Strategies
THURSDAY, 22 JANUARY 2015
NHLI, Imperial College, London Monday 30th March 2015 . APS and the Aerosol Society Joint Symposium.. The European Medicines Agency published its “Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP)” in 2009. The regulatory clarity the guidelines have provided has revealed scientific hurdles particularly relating to how inhalation and regulatory scientists can define bioequivalence for inhaled therapies. A particular challenge has emerged in establishing the nature of in vitro-in vivo correlations and the poor predictability of pulmonary bioavailability data from in vitro pharmaceutical performance testing. This meeting will bring together inhalation scientists from academia, regulatory agencies, innovator, and generic pharmaceutical developers. The symposium will assess the current scientific knowledge base and identify the challenges that must be addressed in identifying appropriate and meaningful in vitro metrics that are predictive of bioavailability. There will be thought-provoking short-talks by key opinion leaders from a regulatory background and from innovator and generic pharmaceutical industrial scientists. The talks will stimulate facilitated breakout sessions to identify opportunities to address the scientific challenges. The symposium aims to establish a consensus ‘white paper’ on the key components of a joint academic-industrial-regulatory research programme to develop tools that support the in vitro approach for OIP licensing.. For more information, to view the programme and to register for the conference, please visit the APS website here: http://www.apsgb.co.uk/EVENTS/20150330/.
 
Follow us
 
Upcoming Events
APS Bioequivalence of Orally Inhaled Drug Products: Joint Meeting with The Aerosol Society
30 March 2015
APS Particle Engineering - Joint Meeting with SSPC
13 - 14 April 2015
APS Industrial Insights 2015
16 - 17 April 2015
APS Board Meeting
28 - 29 April 2015
APS Parkinson's Disease: From Patient to Product
19 May 2015
Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.